Orgenesis Stock Beta
| ORGS Stock | USD 0.51 0.01 2.00% |
Orgenesis fundamentals help investors to digest information that contributes to Orgenesis' financial success or failures. It also enables traders to predict the movement of Orgenesis Stock. The fundamental analysis module provides a way to measure Orgenesis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Orgenesis stock.
Orgenesis | Beta |
Orgenesis Company Beta Analysis
Orgenesis' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Orgenesis Beta | 1.1 |
Most of Orgenesis' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orgenesis is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Orgenesis Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Orgenesis is extremely important. It helps to project a fair market value of Orgenesis Stock properly, considering its historical fundamentals such as Beta. Since Orgenesis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Orgenesis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Orgenesis' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Orgenesis has a Beta of 1.098. This is 27.67% higher than that of the Biotechnology sector and 21.01% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Orgenesis Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orgenesis' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Orgenesis could also be used in its relative valuation, which is a method of valuing Orgenesis by comparing valuation metrics of similar companies.Orgenesis is currently under evaluation in beta category among related companies.
Orgenesis Institutional Holders
Institutional Holdings refers to the ownership stake in Orgenesis that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Orgenesis' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Orgenesis' value.| Shares | Prudential Financial Inc | 2023-12-31 | 11 K | Ubs Group Ag | 2023-12-31 | 1.1 K | Tsfg, Llc | 2023-12-31 | 1.1 K | Bank Of America Corp | 2023-12-31 | 236 | Wells Fargo & Co | 2023-12-31 | 216 | Jpmorgan Chase & Co | 2023-12-31 | 141 | Royal Bank Of Canada | 2023-09-30 | 117 | Bnp Paribas Arbitrage, Sa | 2023-12-31 | 75.0 | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 38.0 | Vanguard Group Inc | 2023-12-31 | 924.8 K | Geode Capital Management, Llc | 2023-12-31 | 239.3 K |
Orgenesis returns are very sensitive to returns on the market. As the market goes up or down, Orgenesis is expected to follow.
Orgenesis Fundamentals
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.65 | ||||
| Operating Margin | (48.42) % | ||||
| Current Valuation | 37.14 M | ||||
| Shares Outstanding | 34.34 M | ||||
| Shares Owned By Insiders | 20.35 % | ||||
| Shares Owned By Institutions | 6.56 % | ||||
| Number Of Shares Shorted | 299.69 K | ||||
| Price To Earning | 7.52 X | ||||
| Price To Book | 1.39 X | ||||
| Price To Sales | 0.61 X | ||||
| Revenue | 530 K | ||||
| Gross Profit | 36.02 M | ||||
| EBITDA | (51.48 M) | ||||
| Net Income | (64.92 M) | ||||
| Cash And Equivalents | 2.3 M | ||||
| Cash Per Share | 0.09 X | ||||
| Total Debt | 3.32 M | ||||
| Debt To Equity | 0.64 % | ||||
| Current Ratio | 1.57 X | ||||
| Book Value Per Share | (0.66) X | ||||
| Cash Flow From Operations | (14.84 M) | ||||
| Short Ratio | 3.78 X | ||||
| Earnings Per Share | (1.91) X | ||||
| Target Price | 6.0 | ||||
| Beta | 1.1 | ||||
| Market Capitalization | 17.58 M | ||||
| Total Asset | 14.55 M | ||||
| Retained Earnings | (176.62 M) | ||||
| Working Capital | (12.33 M) | ||||
| Current Asset | 5.29 M | ||||
| Current Liabilities | 14.92 M | ||||
| Net Asset | 14.55 M |
About Orgenesis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orgenesis's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orgenesis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orgenesis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Orgenesis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Orgenesis' short interest history, or implied volatility extrapolated from Orgenesis options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Orgenesis Piotroski F Score and Orgenesis Altman Z Score analysis. For more information on how to buy Orgenesis Stock please use our How to Invest in Orgenesis guide.Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Orgenesis Stock analysis
When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Orgenesis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orgenesis. If investors know Orgenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orgenesis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.018 | Quarterly Revenue Growth (0.99) | Return On Assets (0.65) | Return On Equity (3.39) |
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Orgenesis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.